A comparative study of dexmedetomidine and propofol for

sedation in the cardiothoracic intensive care unit by Md Ralib, Azrina et al.
12/12/13 2:41 pmA Comparative Study of Dexmedetomidine and Propofol for Sedation in The Cardiothoracic Intensive Care Unit.
Page 1 of 17file:///Volumes/AZRINA%20BACKUP/Writing/Pre-PhD/Dexmedetomidine%20-%20IMJ%20n%20MJMS/Dex%20IMJ/Vol6-No2-B1.htm
Int. Med J Vol. 6 No 2 December 2007
A Comparative Study of Dexmedetomidine and Propofol for
Sedation in The Cardiothoracic Intensive Care Unit.
Azrina Md Ralib 1,  Saedah Ali 2, Mohd Nikman Ahmad 3, Ziyadi Mohd
Ghazali4, Nik Abdullah Nik Mohamad 5.
Department of Anaesthesiology and Intensive Care1,2,3,5, Cardiothoracic Unit,
Department of Surgery4, School of Medical Sciences, Universiti Sains Malaysia,
Kelantan, Malaysia.
ABSTRACT
Introduction and Objectives: The intensive care unit (ICU) is an uncomfortable
and stressful environment for patients. The use of adequate sedation and analgesia
is important to reduce stress to patients. The aim of this study was to compare a
relatively new sedative agent, dexmedetomidine to current sedative agent used,
propofol in the provision of sedation and analgesia, their effects on haemodynamic
and respiratory parameters and cost involved on post open heart surgery patients.
Materials and Methods: A prospective, randomized single-blinded trial was
conducted on post open heart surgery patients in the ICU of the Hospital Universiti
Sains Malaysia (HUSM). Thirty two patients were randomized to dexmedetomidine
or propofol groups. Analgesic requirement, haemodynamic and respiratory
parameters, and extubation time were measured and compared. Mean rate of
infusion to achieve adequate sedation were used to calculate the cost involved in
the use of these two agents. Results: Patients sedated with dexmedetomidine
required significantly lower dose of morphine compared to propofol [mean (sd):
12.80 (2.61) versus 15.86 (1.87) mg/kg/min, p=0.00]. Mean heart rate was also
significantly lower in dexmedetomidine group compared to propofol group [mean
(CI): 74.48 (70.38,78.59) versus 83.85 (79.61,88.09) per minutes, p=0.00].
However there were no significant differences in the other parameters between the
two groups. Cost involved the use of dexmedetomidine was slightly higher
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compared to propofol (RM 9.57 versus RM8.94 per hour). Discussion and
Conclusions: Dexmedetomidine is comparable to propofol in the provision of
sedation, and its effect on haemodynamic and respiratory parameters. However it
has added advantages in the provision of analgesia, and caused a significant
reduction in heart rate. This is beneficial in these patients by reducing myocardial
oxygen demand, and hence subsequent ischaemia and infarction. However, further
larger studies are needed to evaluate the effect of dexmedetomidine on
perioperative cardiac morbidity and mortality.
INTRODUCTION
The intensive care unit (ICU) is an environment of high level of stress and
discomfort for patients. The use of adequate sedation and analgesia are important
in order to modulate physiological response to stress and pain, hence reducing
morbidity and mortality in the ICU. Current sedative agents used in the intensive
care unit include benzodiazepines e.g. midazolam, opioids e.g. morphine, and
propofol. These drugs whilst providing effective sedation and analgesia, have their
own limitations. Benzodiazepines are anxiolytic and amnestic, but they can also
cause paradoxical agitation especially in the elderly. Opioids can provide effective
analgesia, but they are not good sedative and amnestic agent. Furthermore they
can cause pronounce respiratory and cardiovascular depression. Both
benzodiazepines and opioids have cumulative effects, and hence their actions are
prolonged in patients with liver and renal impairment, which are common in the
intensive care setting1. Propofol, which has a very short duration of action and no
cumulative effect, can cause dose-dependent respiratory depression, hypotension
and hyperlipidaemia2.
The search for an ‘ideal’ sedative agent continues. It should be one that is easy to
administer, has a rapid onset and predictable effect, alleviates both pain and
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anxiety, promotes cardiac and respiratory stability, maintains arousability during
sedation, allows rapid recovery after discontinuation, lack of drug accumulation, few
adverse events and interact minimally with other drugs and inexpensive3.
Dexmedetomidine is a relatively new highly selective a2 agonist agent (a2 : a1  ratio
of 1600 : 1). It is a potent sedative, anxiolytic, analgesic and sympatholytic agent,
currently being introduced in our intensive care setting. It acts both centrally and
peripherally. At the central nervous system, it acts on the postsynaptic a2 inhibitory
receptor, resulting in sympatholytic and sedative effects. Its action at the spinal
cord results in analgesic effect, whereas its action at the presynaptic membrane of
the peripheral nerves and autonomic ganglia, reduces the release of catecholamines
leading to sympatholytic effect4.
In the cardiothoracic intensive care unit of Hospital Universiti Sains Malaysia
(HUSM), the current standard for sedation and analgesia are propofol and morphine
infusions. Propofol has a rapid onset and a very short duration of action. However it
has been associated with dose-dependent respiratory depression, hypotension and
hyperlipidaemia2. Hence, it can exert deteriorating effects in patients with limited
myocardial reserve. Previous studies have concluded that dexmedetomidine has
several unique properties including provision of effective sedative and analgesic
effects, maintenance of patients’ arousability and cooperativity, reduction of heart
rate, and hence myocardial oxygen demand with minimal effects on ventilation5.
With the advent of this new sedative agent with its unique properties, we aimed to
compare it with our standard regime, in order to provide an alternative or better
sedative regime to our patients.
MATERIALS AND METHODS
This study was a prospective, randomized, single-blinded trial. It had been
approved by the Research and Ethics Committee, School of Medical Science,
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Universiti Sains Malaysia, Kubang Kerian, Kelantan. Thirty-two post-open heart
surgical patients whom were being mechanically ventilated in the Cardiothoracic
Intensive Care Unit (CICU) of Hospital Universiti Sains Malaysia (HUSM) from
January 2003 until July 2005 were enrolled in this study after obtaining their
informed consent. Based on previous studies by Venn et al.17 and Venn & Ground11,
heart rate reduction of clinical interest was 20%. A sample size of 32 (n=16 in each
group) were needed to achieve a significance level of 5% and power of study of
80%. Inclusion criteria includes; male and female above 18 years of age, and
written consent. Exclusion criteria of this study includes; poor left ventricular
function (ejection fraction < 40% / cardiac index < 2 l/min/m2), preexisting severe
bradycardia (heart rate < 40 per minute) or heart block of any degree, chronic
medical illness e.g. renal, liver or neurological impairment, any other conditions or
factors that might increase risk to the patients e.g. haemodynamic instability
perioperatively, body mass index > 30, and any contraindication or known or
suspected allergy to propofol, dexmedetomidine, benzodiazepine or opioid.
The objectives of this study were to assess the effect of dexmedetomidine
compared to propofol on haemodynamic and respiratory parameters, to assess their
efficacy in the provision of sedation and analgesia, and to compare the cost involved
in the use of these two drugs. Patients were randomized into two study arms,
dexmedetomidine and propofol group. Intraoperatively, patients were induced with
fentanyl, midazolam and pancuronium. Anaesthesia was maintained with isoflurane
as inhalational agent and pancuronium as muscle relaxant. The infusion was started
in the operation theatre at the start of skin closure, once the patient was
haemodynamically stabilized with minimal amount of inotropes.
The infusion rate was titrated to achieve bispectral index score (BIS) of 65 to 85 to
maintain adequate sedation6. Morphine infusion of 0.01 mg/kg/hour was started in
the ICU, for both groups. If the blood pressure and heart rate increased more than
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20% from the baseline despite on adequate sedation, rescue morphine 1 mg bolus
was given. Patients were ventilated in the CICU. Weaning criteria includes; alert,
conscious, no neurological deficit, cooperative, comfortable, normothermia,
cardiovascular stability; MAP > 70 mmHg with minimal inotropic support, stable
heart rate and rhythm, PaO2 > 75mmHg, FiO2 < 40%, PEEP < 5 cmH2O, and no
excessive bleeding from surgical drain. The study drug was stopped during weaning,
prior to extubation. Extubation was undertaken when spontaneous respiration with
pressure support < 10cmH2O, VT > 6ml/kg and respiratory rate > 10 but < 20  per
minute.
The outcomes of this study include haemodynamic parameters (heart rate, systolic
and diastolic blood pressure), respiratory parameters (PF ratio (PaO2/Fi02), and
pCO2 level), metabolic parameters (serum lactate, and pH), bispectral index score
(BIS), total morphine requirement, and extubation time. Cost was calculated from
the mean rate of infusion of study drug required to achieve adequate sedation.
All data analysis and data entry were done using Social Science and Statistical
Packaged (SPSS) version 10.0 software licensed to Universiti Sains Malaysia.
Results were presented as mean (standard deviation), unless otherwise stated.
Statistical analyses were performed using independent t-test or Mann-Whitney U
test for numerical data and Chi-Square test for categorical data. Haemodynamic
and respiratory data were compared using analysis of variance (ANOVA) for
repeated measures. Statistical significance was considered at p value less than
0.05.
RESULTS
A total of 36 patients were included in the study. Four patients were excluded from
the study after randomization; two due to severe bleeding affecting haemodynamic
parameters, one due to development of significant arrhythmia unrelated to the
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study drug, and one due to severe hypotension secondary to cardiogenic shock post
cardiopulmonary bypass. There were no significant differences in the demographic
and sedative characteristics between the two groups (Table 1).
Mean heart rate in propofol group was 83.85 (79.61, 88.09) and in
dexmedetomidine group was 74.48 (70.38, 78.59). From repeated measures
ANOVA, mean heart rate in dexmedetomidine group was significantly lower than in
the propofol group (p = 0.00) (Figure 1). There were no significant differences in
mean systolic blood pressure, diastolic pressure, PaO2/FiO2 ratio, PaCO2, pH,
serum lactate and bispectral index score (BIS) between the two groups.
Morphine requirement (mg/kg/hour) during study drug infusion in dexmedetomidine
group was significantly lower than in propofol group (Mean (CI): 74.48 (70.38,
78.59) versus 83.85 (79.61, 88.09) (Table 2). There was no significant different in
extubation time after discontinuation of study drug infusion in the two groups. The
cost involved in sedating an average 70 kg man in dexmedetomidine group was
slightly higher compared to propofol group (RM 9.57 versus RM 8.94 per hour).
DISCUSSION
This study only involved post open heart surgical patients whom were being
mechanically ventilated in the cardiothoracic ICU (CICU). This was mainly due to
the homogeneity of this group of patients in terms of underlying diseases and type
of anaesthesia and surgery. The result hence could only be extrapolated to this
population of patients. It could not be generalized to the general ICU settings.
Administrations of loading dose were omitted in both groups. Rapid infusion of
loading dose of dexmedetomidine has been associated with a biphasic response,
transient hypertension followed by severe hypotension7,8. Activation of peripheral
α2-adrenoreceptors in blood vessels mediates vascular smooth muscle contraction,
transiently increasing vascular resistance. This is followed by activation of
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postsynaptic receptors in the central nervous system, which then induces centrally
mediated sympatholysis, lowering blood pressure7. Large bolus of propofol used as
in induction of anaesthesia has also been associated with the occurrence of
significant hypotension and bradycardia9,10. To avoid the occurrence of these
responses, large rapid bolus of loading doses were omitted in both groups. Both
study drugs were instituted in the operation theatre at the start of sternal closure.
Average time from sternal closure to patients arrival in CICU were about 1 hour.
This was sufficient for adequate plasma level and depth of sedation when patients
reached CICU.
There were no statistically significant differences in mean age, weight, height and
gender between dexmedetomidine and propofol groups. The ethnic group distribution showed that
majority of patients were Malay, which contributed to 81.25% (26) of the total patients as compared to
18.75% (6) Chinese. This was due to the higher percentage of Malay population in the study area.
However, there were no statistically significant differences in the ethnic distribution between the two
groups. The use of intraoperative fentanyl and the duration of sedation were not significantly different
between the two groups. Hence, these effects can be eliminated when analyzing the results of this study.
 
Patients sedated with dexmedetomidine had significantly lower heart rate compared
to patients sedated with propofol [mean(CI): 74.48 (70.38,78.59) versus 83.85
(79.61,88.09)]. The significant difference between the two groups was similar to a
study by Venn & Ground11. However Herr et al.7 did not show any significant
difference in heart rate between these two groups. Reduction in heart rate is
expected from the known pharmacology of dexmedetomidine, an α2 adrenoceptor
agonist12. It may be due to two pathways: a vagomimetic effect and blockade of
cardioaccelerator nerve13. Other studies in healthy volunteers and in ICU patients,
also showed a significant reduction in heart rate when compared to
placebo14,15,16,17.
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This reduction in heart rate can theoretically reduce myocardial oxygen demand,
and hence subsequent ischaemia and infarction. This is of major importance in
critically ill patients, especially during periods of stress e.g. endotracheal suctioning,
physiotherapy, and mobilization. Stress is considered to be a major risk factor in
myocardial ischaemia after surgery. Although no study has been conducted on
dexmedetomidine on the incidence of ischemia, two other α2 adrenoceptor agonists;
mivazerol and clonidine have been shown to reduce ischaemia18,19,20. American
College of Cardiology/American Heart Association (ACC/AHA) guideline has
conferred the use of α2-adrenoceptor agonist as a grade IIb recommendation in the
2002 guideline update on perioperative cardiovascular evaluation for non-cardiac
surgery. Since the use of b-blocker had been proven to significantly reduce
perioperative cardiac morbidity and mortality, a2-agonists were recommended in
patients whom b-blockers are contraindicated21.
 
There were no significant differences in mean systolic blood pressure and diastolic
blood pressure between dexmedetomidine and propofol, similar to a study by Venn
& Ground11. Herr et al.7 showed a slight decreased in mean blood pressure in
dexmedetomidine patients compared to propofol patients. However this finding was
not clinically important. Other studies that demonstrated the safety of
dexmedetomidine have shown that there were no significant differences in blood
pressure when compared to placebo groups17,22.
 
Mean PF ratios (PaO2/FiO2 ratios) were not significantly different between
dexmedetomidine and propofol groups. Similarly, Venn & Ground11 did not show
any significant difference in mean PaO2/FiO2 ratios between dexmedetomidine and
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propofol. However, when compared to placebo, Venn et al.23 showed a significantly
higher mean PaO2/FiO2 ratio in dexmedetomidine group. Previous studies have
shown that there were no clinically important adverse effects on ventilation7,23,24.
This finding was similar as in this study.  Mean PaCO2 levels were not significantly
different between the two groups. Dexmedetomidine has been shown to be safe
when continued post extubation with no effect on ventilation17. Mean serum lactate
and pH were also not significantly different between dexmedetomidine and propofol
groups. These may be due to stable haemodynamic and respiratory parameters
associated with the use of these two agents. Similarly, Venn & Grounds11 did not
show any difference in mean pH and base excess between the two groups.
 
Bispectral index score was used to maintain adequate sedation between the two
groups. Triltisch et al.22 used BIS as a guidance of sedation when comparing
dexmedetomidine and placebo for sedation in the ICU. They found that BIS-guided
sedation seems to be suitable during administration of dexmedetomidine, similar to
other sedation regimes in surgical ICU settings. Mean BIS values between the two
groups were not significantly different, indicating equivalent levels of sedation. Most
other studies commonly used Ramsay sedation scale as an assessment of sedation.
In this study, Ramsay sedation score was initially used in the sedation scale of these
patients along with BIS. However there was a lot of interrater variability in scoring
these patients. Furthermore, the use of Ramsay sedation scale necessitates the use
of acoustic and tactile stimulation. These manipulations can cause undesired arousal
and agitation leading to patients discomfort and a possible increase in sedative and
analgesic drug requirements22. Due to these reasons, this parameter was excluded
from the study and only bispectral index score was used. Previous studies have
shown that there were good correlations between BIS and Ramsay sedation
scale25,26.  
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Patients sedated with dexmedetomidine needed lower dose of morphine compared
to propofol [mean (sd): 12.80 (2.61) vs 15.86 (1.87) mg/kg/min]. This was
consistent to the finding of previous studies on ICU patients, which demonstrated
that dexmedetomidine reduced the use of concurrent analgesia7,11,17,22. Studies on
healthy volunteers have also demonstrated its analgesic effect27,28,29. Mechanism
of analgesia effect is postulated to be due to its binding to a2-adrenoreceptors in
the intermediolateral cell column and the substantia gelatinosa of the dorsal horn of
the spinal cord8. Supraspinal and peripheral sites of analgesic action have also been
reported12. This analgesic property of dexmedetomidine is one of its unique
features. Ebert3 described one of the properties of ideal sedative agent is to
alleviate both pain and anxiety. Other commonly used sedative agents such as
midazolam and propofol have no analgesic effect, necessitating the use of
concurrent analgesia in postoperative patients. However, the potency of its
analgesic effect was low compared to other analgesic drugs. Dexmedetomidine
could not be use as a sole agent in major operation e.g. CABG. Concurrent use of
other analgesic drugs is still needed, however to much less extent compared with
the use of other sedative agents.
Times to extubation were not significantly different between dexmedetomidine and
propofol groups. This may be due to rapid distribution half life (t½ α) of both drugs,
dexmedetomidine; 6 minutes and propofol; 1.8 to 4 minutes8,30. This finding was
similar to previous studies7,11. Both propofol and dexmedetomidine did not exhibit
accumulation effect even after prolonged infusion31,32,33. The elimination half life
(t½ b) of dexmedetomidine was longer compared to propofol (2 hours versus 21 to
69 minutes)8,30. However, dexmedetomidine has been shown to be safe when
continued post extubation with no effect on ventilation17. This may not affect the
decision for extubation in patients sedated with dexmedetomidine. Hence,
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extubation times did not differ between the two groups despite longer elimination
half life (t½ b) of dexmedetomidine.
To calculate the cost involved in the use of these sedative agents, mean rate of
infusion used to achieve adequate sedation was used. Cost involved in sedating an
average 70 kg man was calculated in each group. Cost involved in the use of
dexmedetomidine was slightly higher than propofol (RM 9.57 versus RM 8.94 per
hour). On an average of 12 hours of sedation, the cost involved in dexmedetomidine
was only RM 7.56 higher than propofol [(RM 9.57 – RM 8.94) x 12 hours]. However,
the use of morphine was lower in dexmedetomidine group compared to propofol.
Taken these factors into account, the cost involved in the use of dexmedetomidine
was almost similar to propofol.
This study showed that dexmedetomidine was comparable to propofol in the
provision of sedation in post open heart surgical patients with preserved left
ventricular function and similar co-morbidities. However it has added advantage in
the provision of analgesia, as shown by lower morphine requirement with the use of
dexmedetomidine. Haemodynamic, respiratory and metabolic effects of both drugs
were comparable. A significant property of dexmedetomidine shown in this study
was reduction in heart rate. This is beneficial in these patients by reducing
myocardial oxygen demand, and hence subsequent ischaemia and infarction.
However, further large randomized trials are needed to evaluate the effect of this
newest selective a2-agonist, dexmedetomidine on perioperative cardiac morbidity
and mortality.
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TABLES
Table 1: Demographic and Sedative Characteristics
Variables Dexmedetomidine Propofol p value
 Mean (SD) Mean (SD)  
Age (years) 52.44 12.90 55.38 12.26 0.51a
Weight (kg) 66.44 11.50 59.81 8.92 0.08a
Height (cm) 162.50 9.70 160.94 7.83 0.62a
Duration of
sedation (hour)
 
12.47
 
4.10
 
11.88
 
3.65
 
0.67a
Intraoperative
fentanyl (mg)
 
903.10
 
157.55
 
862.50
 
173.69
 
0.49a
 Frequency (%) Frequency (%)  
Gender
Male
Female
 
9
7
 
56.3%
43.7%
 
11
5
 
68.8%
31.3%
 
0.45b
Race
Malay
Chinese
 
12
4
 
75.0%
25.0%
 
14
2
 
87.5%
12.5%
 
0.37b
                            Note: All variables were approximately normally
distributed.
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                                    a  Independent T test
                                    b Pearson Chi-Square test
Table 2: Morphine requirement (µg/kg/hour)
Variable Morphine p value
 
(mg/kg/hour) Mean (SD)
Propofol 15.86 1.87 0.00a
Dexmedetomidine 12.80 2.61
                                                Note: Variable was approximately
normally distributed
                                                                a Independent T test
FIGURE
 
 
Figure 1: Mean heart rate
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